Opioid Dependence Clinical Trial
Official title:
START Follow-up Study (NIDA CTN Protocol 0050)
The purpose of the study is to conduct a follow-up of substance abuse patients (n=1,269)
about 2 to 5 years since they were originally recruited from 8 substance abuse treatment
clinics (located in 5 states) to participate in a prior clinical trial study called "START"
(Starting Treatment with Agonist Replacement Therapies). The START Follow-up Study will be
conducted over 5 years and will involve three follow-up interviews with START participants.
The specific aims of the START Follow-up Study are as follows.
1. To determine longer-term outcomes of Suboxone versus methadone treatment received in
the START
2. To investigate patient and treatment factors associated with post-START treatment
access, utilization, and outcomes among Suboxone and methadone patients
3. To explore other correlates of the long-term outcomes among START patients.
The primary outcome is the trajectory of opioid use since START entry, operationalized as
number of days using opioids per month over the follow-up period since START enrollment.
Other long-term outcomes of interest will include alcohol and other drug use, mental and
physical health, quality of life, criminal justice status, HIV/HCV risk behaviors, and
mortality. Treatment access and utilization factors of interest will include: predisposing
personal factors, treatment experiences, and perceptions and attitudes toward treatment.
Other correlates of interest will include cognitive functioning, mental health functioning,
and social support.
2.2 Hypotheses There will be no differences in long-term outcomes of participants randomized
to Suboxone treatment versus methadone treatment. To assess this outcome, trajectories of
opioid use (operationalized as number of days using opioids per month over the follow-up
period since START enrollment) will be analyzed. Other secondary long-term outcomes of
interest will also be analyzed and will include alcohol and other drug use, mental and
physical health, quality of life, criminal justice status, HIV/HCV risk behaviors, and
mortality. Participants with greater access and utilization of treatment, fewer predisposing
personal factors, greater social support, and more positive perceptions and attitudes toward
treatment, will be more likely to be a member of the low or decreasing drug use
trajectories.
2.3 Study Design This longitudinal, observational study will involve contacting the study
participants from the original START study for future assessments. The study is expected to
be completed in five years.
The follow-up study will consist of three interviews of the START study participants,
beginning approximately 2 to 5 years after initial enrollment in the START study and will
assess these participants over a 5-year period to provide long-term outcome data 7 to 10
years after START enrollment. This study information will be supplemented by (electronic)
medical and other administrative records, as available. An intent-to-treat design will be
adopted to include all 1,269 study participants enrolled in START.
Figure 1 presents a summary of the timeline for the conduct of project activities. There
will be three participant interviews over the five years of the project. After receiving IRB
approval for the conduct of the study, the START community treatment provider (CTP) or Node
staff will contact their START participants, obtain participant consent to take part in the
follow-up study, and conduct the initial assessment. This assessment will take place in the
clinic if possible and by phone if the participant is not able to come in person.
By agreeing to take part in this study the participant will agree to:
1. Updating their locator information initially and throughout the duration of the study;
2. Sharing of clinic and survey data with the lead research team (UCLA);
3. Completing various assessments and providing urine and oral fluid/blood specimens for
lab assessments;
4. Providing access to administrative records (e.g., medical records, criminal justice
records);
5. Being contacted by the study staff for 2 more interviews in person or by phone
(consented prior to each interview).
Local CTP or Node staff will conduct the Visit 1 interview in Years 1-2 of the START
follow-up study. Enrollment for the Visit 1 interview will remain open for the life of the
study to allow sites that are able to continue to seek participants for Visit 1 beyond Year
2 of the study to do so. The Lead Node staff will conduct the Visit 2 interview by telephone
approximately 12 months after the completion of Visit 1. The Lead Node and/or CTP staff will
conduct another participant interview approximately 12-18 months after Visit 2 is completed.
If a study participant is found late in the study progress for Visit 1, the following
visits, 2 and 3 will occur sooner than originally planned, but as far apart as possible. All
assessments are completed by the end of Year 5 of the START follow-up study.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03675386 -
Reducing Opioid Use for Chronic Pain Patients Following Surgery
|
N/A | |
Completed |
NCT02593474 -
Medication-Assisted Treatment for Youth With Substance Use Disorders
|
Phase 1 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT02294253 -
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
|
Phase 2/Phase 3 | |
Terminated |
NCT00768482 -
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
|
Phase 3 | |
Completed |
NCT01741350 -
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
|
N/A | |
Terminated |
NCT04121546 -
Collaborative Care for Opioid Dependence And Pain Pilot Study
|
N/A | |
Withdrawn |
NCT03368794 -
Naloxone to TReatment Entry in the Emergency Setting
|
N/A | |
Completed |
NCT03447743 -
Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
|
Early Phase 1 | |
Completed |
NCT04464421 -
SMART Effectiveness Trial
|
N/A | |
Recruiting |
NCT04189523 -
Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage
|
N/A | |
Completed |
NCT03305666 -
Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
|
Phase 4 | |
Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
Not yet recruiting |
NCT03813095 -
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
|
Phase 2 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT01895270 -
Improving Buprenorphine Detoxification Outcomes With Isradipine
|
Phase 1/Phase 2 | |
Completed |
NCT01717963 -
Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
|
Phase 3 | |
Completed |
NCT01425060 -
Improving Effective Contraceptive Use Among Opioid-maintained Women
|
Phase 1 | |
Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
Completed |
NCT01188421 -
Medications Development for Drug Abuse Disorders
|
Phase 1/Phase 2 |